Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 9, 2016
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study"Walter Fries, Anna Viola, Natalia Manetti, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 6, 2025
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensusGionata Fiorino, Flavio Andrea Caprioli, Sara Onali, et al.Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.Inflammatory Bowel Diseases|May 17, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational StudyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.Journal of Crohn'S & Colitis|November 3, 2025
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment classTommaso Innocenti, Jurij Hanžel, Marie Truyens, et al.Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.Intestinal Research|September 29, 2025
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Francesco Costa, et al.Pageof 7